Cancer cells can develop resistance to CDK4/6 inhibitors through various mechanisms, including adaptive alterations in cell cycle regulatory pathways, reactive activation of bypass signalling pathways, and interactions with cancer-related immune cells in the microenvironment (Figure 1). The gene discussed is CDK4; the disease is cancer.